Q-omics provides the consensus-scored RN7SKP259 profile across patient tissues and cancer cell-line models. RN7SKP259 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RN7SKP259 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RN7SKP259 RNA expression shows 11,130 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, and UVM as cancer lineages where RN7SKP259 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP259 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP259 survival associations across molecular data types. RN7SKP259 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP259 RNA expression–survival associations across cancer types. High RN7SKP259 expression shows unfavorable associations in COAD, ACC, BRCA, UVM, HNSC and OV. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RN7SKP259 RNA expression.
This table summarizes RN7SKP259 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP259. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP259 shows lower tumor expression in THCA and higher tumor expression in COAD, KIRC, BRCA and LIHC. The COAD box plot shows higher RN7SKP259 RNA expression in tumor versus normal tissue (log2 FC = +0.086, t-test p = .005).
This table shows molecular features associated with RN7SKP259 in patient tissues and cancer cell lines. In patient samples, RN7SKP259 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
